Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Antônio Carlos Avenue, 6627 Belo Horizonte, Minas Gerais 31270-901, Brazil.
Mol Biol Rep. 2012 Jul;39(7):7541-8. doi: 10.1007/s11033-012-1588-x. Epub 2012 Feb 19.
Type 2 diabetes mellitus is a metabolic, vascular, and neuropathic disease with a high risk of atherosclerotic events due to dyslipidemic states. Polymorphisms in Apolipoprotein A5 gene (APOA5) have been associated with increased triglyceride levels in many different populations. This study aimed to identify the frequencies of the APOA5 -1131T>C and SW19 polymorphisms and evaluate their effects on lipid levels in patients with type 2 diabetes. Genotyping of APOA5 -1131T>C and SW19 polymorphisms was performed by PCR-RFLP in 146 diabetic patients and in controls (n = 173), from 30 to 80 years of age. Diabetic patients were divided into two groups: patients not treated with lipid lowering drugs (group G1; n = 62) and those treated with lipid lowering drugs (group G2, n = 84). Lipids and lipoproteins were determined enzymatically. Among participants not treated with lipid-lowering drugs (diabetics G1 and controls; n = 235), the -1131C was associated with lower LDLc levels (p = 0.015). In the diabetic patients, the 19W allele was associated with higher triglyceride levels (p = 0.004). In G1 diabetic patients, the combined analysis of APOA5 -1131T>C and SW19 polymorphisms showed that [TC or CC] + SS carriers presented lower total cholesterol levels than did other genotype combinations (p = 0.049). It could therefore be concluded that APOA5 -1131T>C and SW19 polymorphisms influence lipid levels in type 2 diabetic patients.
2 型糖尿病是一种代谢性、血管性和神经病变疾病，由于血脂异常状态，其发生动脉粥样硬化事件的风险较高。载脂蛋白 A5 基因（APOA5）的多态性与许多不同人群的甘油三酯水平升高有关。本研究旨在确定 APOA5-1131T>C 和 SW19 多态性的频率，并评估它们对 2 型糖尿病患者血脂水平的影响。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）对 146 例糖尿病患者和对照组（n=173）的 APOA5-1131T>C 和 SW19 多态性进行基因分型，年龄在 30 至 80 岁之间。将糖尿病患者分为两组：未用降脂药物治疗的患者（G1 组；n=62）和用降脂药物治疗的患者（G2 组，n=84）。通过酶法测定血脂和脂蛋白。在未用降脂药物治疗的患者（糖尿病患者 G1 和对照组；n=235）中，-1131C 与 LDLc 水平降低相关（p=0.015）。在糖尿病患者中，19W 等位基因与甘油三酯水平升高相关（p=0.004）。在 G1 糖尿病患者中，APOA5-1131T>C 和 SW19 多态性的联合分析显示，[TC 或 CC]+SS 携带者的总胆固醇水平低于其他基因型组合（p=0.049）。因此，可以得出结论，APOA5-1131T>C 和 SW19 多态性影响 2 型糖尿病患者的血脂水平。
